Moderate

Narcolepsy and idiopathic hypersomnia

Central disorders of hypersomnolence · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic disorders of excessive daytime sleepiness; narcolepsy type 1 features cataplexy and loss of hypocretin neurons, while type 2 and idiopathic hypersomnia lack cataplexy. Diagnosis requires sleep studies and management combines scheduled naps with stimulant and anticataplectic therapy.

Red flags

  • Cataplexy triggered by emotion (status cataplecticus if abrupt withdrawal)
  • Undiagnosed obstructive sleep apnoea
  • Falls asleep driving
  • Cardiovascular disease limiting stimulant use
  • Severe mood disorder

Assessment

Differential diagnosis

  • Obstructive sleep apnoea
  • Insufficient sleep syndrome
  • Depression and other mood disorders
  • Idiopathic hypersomnia
  • Circadian rhythm disorders
  • Medication-induced sedation

Investigations

  • Overnight polysomnography followed by multiple sleep latency test (MSLT)
  • Epworth Sleepiness Scale
  • CSF hypocretin-1 (low in narcolepsy type 1) in selected cases
  • HLA-DQB1*06:02 typing (supportive, not diagnostic)
  • Exclude sleep apnoea and insufficient sleep first
  • Actigraphy/sleep diary to confirm adequate sleep opportunity

Management

  • Establish chronic excessive daytime sleepiness and screen for cataplexy
  • Exclude obstructive sleep apnoea and insufficient or shift-related sleep
  • Confirm with polysomnography and MSLT (short sleep latency, sleep-onset REM periods)
  • Measure CSF hypocretin where narcolepsy type 1 is suspected
  • Advise scheduled short naps and strict sleep hygiene
  • Start a wake-promoting agent for daytime sleepiness
  • Add an anticataplectic agent for narcolepsy with cataplexy
  • Consider sodium oxybate for severe sleepiness and cataplexy
  • Counsel on driving, occupation and safety
  • Arrange sleep-service follow-up and treat comorbidities

Drugs & doses

Modafinil 100-400 mg PO daily (wake-promoting)
Methylphenidate or dexamfetamine for refractory sleepiness
Pitolisant 4.5-36 mg PO daily (histamine H3 antagonist)
Solriamfetol 75-150 mg PO daily
Sodium oxybate 2.25-4.5 g per night in two divided doses (sleepiness and cataplexy)
Venlafaxine or clomipramine as anticataplectic alternatives

Disposition

Specialist sleep service. Driving advice per local regulations. Long-term pharmacological and behavioural management.

Complications & pitfalls

  • Motor vehicle and occupational accidents
  • Cataplexy-related injury
  • Cardiovascular effects of stimulants
  • Social and occupational impairment
  • Depression and reduced quality of life

Exam pearls

  • Sleep-onset REM periods on MSLT and low CSF hypocretin support narcolepsy type 1
  • Always exclude obstructive sleep apnoea and insufficient sleep first
  • Abruptly stopping anticataplectics can precipitate status cataplecticus
  • Scheduled naps are a cornerstone of non-drug management

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.